Paradigm Bioventures
Paradigm Biopharmaceuticals is a late-stage drug development company working with world leaders in pharmaceutical product development to approach science from a different angle. The company is focused on repurposing the drug pentosan polysulfate sodium (PPS) to treat osteoarthritis, mucopolysaccharidosis, heart failure and other chronic diseases. Paradigm Biopharmaceuticals is headquartered in Melbourne Australia and is publicly traded on the Australian Securities Exchange (ASX:PAR). Industries it has a preference for include: Biotechnology, Healthcare, Industrials, Information Technology, Medical Devices & Equipment.